Eris Lifesciences Gets ₹17 Cr GST Notice Linked to Novartis Trademark Deal

has received a show cause cum demand notice from GST authorities alleging non-payment of IGST on its 2019 acquisition of Novartis’ trademark rights for the brand Zomelis and related assets. The notice estimates an IGST liability of ₹16.85 crore along with 18% annual interest from November 27, 2019, though no penalty has been specified. The company has said it will respond within the stipulated timeline after consulting its tax advisors, while maintaining that its compliance practices are robust, aligned with industry norms, and that it has a strong case on merits. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.